Vascular Risk Reduction

Ages 45 Years & Older

Previous Heart Attack, Stroke, or PAD and are Overweight

Have you considered participating in a clinical study?

Participating in a clinical study can improve future treatment options for you and other people with cardiovascular diseases.

Research has shown that treatment with semaglutide may reduce the risk of stroke and heart attack in people with type 2 diabetes. In a study called SELECT, we will check to see if semaglutide reduces the risk of cardiovascular events such as heart attack and stroke in people with overweight or obesity.

You may qualify to participate in the SELECT study if:

  • You have had a brain attack (stroke), or heart attack (myocardial infarction), or have poor circulation (peripheral arterial disease)
  • You are 45 years old or older
  • You are overweight or living with obesity
  • You are able to attend regular clinic visits and receive phone calls over a period of 3—5 years

If you qualified to participate the following would be provided at no cost to you:

  • Study-related care, including regular health check-ups
  • General talks with a dedicated team of doctors and nurses
  • Guidance on healthy lifestyle choices

Contact Us to Participate

If you qualify to participate in a clinical trial based upon one of your medical conditions, then the medical care and medication for that medical condition will be provided at no cost to you and you will receive financial compensation for your time & travel.

Tell us a little bit about yourself and we’ll contact you for further information to determine eligibility for current and future studies.

Please note that any information you provide below is stored securely and will not be shared with anyone outside of Oviedo Medical Research. We will use this information only to help us determine if you qualify for participation in one of our studies.

Get the latest news and updates from Oviedo Medical Research delivered straight to your inbox.

  • This field is for validation purposes and should be left unchanged.